Journals of Gerontology Series A: Biological Sciences and Medical Sciences Large Type Edition
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calof, O. M.
Right arrow Articles by Bhasin, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calof, O. M.
Right arrow Articles by Bhasin, S.
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:1451-1457 (2005)
© 2005 The Gerontological Society of America

Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials

Olga M. Calof1, Atam B. Singh1, Martin L. Lee1, Anne M. Kenny2, Randall J. Urban3, Joyce L. Tenover4 and Shalender Bhasin1,

1 Charles Drew University, Los Angeles, California.
2 University of Connecticut, Farmington.
3 University of Texas, Medical Branch, Galveston.
4 Wesley Woods Hospital, Atlanta, Georgia.

Address correspondence to Shalender Bhasin, Boston University, School of Medicine, E201, 88 E. Newton Street, Boston, MA 02118. E-mail: bhasin{at}bu.edu

Background. We performed a meta-analysis of randomized clinical trials to determine the risks of adverse events associated with testosterone replacement in older men.

Methods. The MEDLINE database was searched from 1966 to April 2004, using testosterone as the indexing term; limits included human, male, ≥45 years old, and randomized controlled trial. Of the 417 studies thus identified, 19 met the inclusion criteria: testosterone replacement for at least 90 days, men ≥45 years old with low or low-normal testosterone level, randomized controlled trial, and medically stable men. Odds ratios (ORs) were pooled using a random effects model, assuming heterogeneous results across studies, and were weighted for sample size.

Results. In the 19 studies that met eligibility criteria, 651 men were treated with testosterone and 433 with placebo. The combined rate of all prostate events was significantly greater in testosterone-treated men than in placebo-treated men (OR = 1.78, 95% confidence interval [CI], 1.07–2.95). Rates of prostate cancer, prostate-specific antigen (PSA) >4 ng/ml, and prostate biopsies were numerically higher in the testosterone group than in the placebo group, although differences between the groups were not individually statistically significant. Testosterone-treated men were nearly four times as likely to have hematocrit >50% as placebo-treated men (OR = 3.69, 95% CI, 1.82–7.51). The frequency of cardiovascular events, sleep apnea or death was not significantly different between the two groups.

Conclusions. Testosterone replacement in older men was associated with a significantly higher risk of detection of prostate events and of hematocrit >50% than was placebo; hematocrit increase was the most frequent adverse event associated with testosterone replacement. These data reaffirm the need to monitor hematocrit, PSA, and digital examination of the prostate during testosterone replacement in older men.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. Zitzmann and E. Nieschlag
Androgen Receptor Gene CAG Repeat Length and Body Mass Index Modulate the Safety of Long-Term Intramuscular Testosterone Undecanoate Therapy in Hypogonadal Men
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3844 - 3853.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. L. Ries, G. S. Bauldoff, B. W. Carlin, R. Casaburi, C. F. Emery, D. A. Mahler, B. Make, C. L. Rochester, R. ZuWallack, and C. Herrerias
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines
Chest, May 1, 2007; 131(5_suppl): 4S - 42S.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Bhasin, R. A. Parker, F. Sattler, R. Haubrich, B. Alston, T. Umbleja, C. M. Shikuma, and for the AIDS Clinical Trials Group Protocol A5079
Effects of Testosterone Supplementation on Whole Body and Regional Fat Mass and Distribution in Human Immunodeficiency Virus-Infected Men with Abdominal Obesity
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1049 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. C. W. Wu
Guideline for Male Testosterone Therapy: A European Perspective
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 418 - 419.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Bhasin, G. R. Cunningham, F. J. Hayes, A. M. Matsumoto, P. J. Snyder, R. S. Swerdloff, and V. M. Montori
Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 1995 - 2010.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. J. Tracz, K. Sideras, E. R. Bolona, R. M. Haddad, C. C. Kennedy, M. V. Uraga, S. M. Caples, P. J. Erwin, and V. M. Montori
Testosterone Use in Men and Its Effects on Bone Health. A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2011 - 2016.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
All GSA journals The Gerontologist
Journals of Gerontology Series B: Psychological Sciences and Social Sciences
Copyright © 2005 by The Gerontological Society of America.